biotech · Pulmonary Arterial Hypertension · Pulmonary Arterial Hypertension (PAH) · IKT
Inhibikase Therapeutics drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 5 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Inhibikase Therapeutics drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Antineoplastic and immunomodulating agents (L01) compound in Inhibikase Therapeutics's portfolio. Mechanism: Tyrosine-protein kinase ABL inhibitor.
US regulatory status: approved. Molecular target: Bcr/Abl fusion protein.
Development asset linked to Inhibikase Therapeutics in public FDA and regional records.
Development asset linked to Inhibikase Therapeutics in public FDA and regional records.
Development asset linked to Inhibikase Therapeutics in public FDA and regional records.